Edwards Lifesciences Co. (NYSE:EW) Receives Consensus Rating of “Hold” from Analysts

Shares of Edwards Lifesciences Co. (NYSE:EW) have been assigned a consensus recommendation of “Hold” from the twenty-six analysts that are presently covering the firm, MarketBeat Ratings reports. Fifteen investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $79.40.

A number of research firms recently issued reports on EW. Barclays lifted their target price on Edwards Lifesciences from $85.00 to $88.00 and gave the company an “overweight” rating in a research report on Monday, December 2nd. Evercore ISI lowered their price target on Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating on the stock in a research report on Tuesday, October 1st. Royal Bank of Canada increased their price objective on Edwards Lifesciences from $80.00 to $85.00 and gave the company an “outperform” rating in a report on Thursday, December 5th. JPMorgan Chase & Co. boosted their target price on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a report on Friday, October 25th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $90.00 price target on shares of Edwards Lifesciences in a research note on Thursday, September 12th.

Insiders Place Their Bets

In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of Edwards Lifesciences stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the transaction, the insider now directly owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. The trade was a 11.18 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Daniel J. Lippis sold 2,500 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $74.08, for a total value of $185,200.00. Following the completion of the transaction, the vice president now directly owns 23,189 shares in the company, valued at approximately $1,717,841.12. This represents a 9.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 37,500 shares of company stock valued at $2,508,350. 1.29% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Edwards Lifesciences

Large investors have recently bought and sold shares of the stock. FSA Wealth Management LLC acquired a new position in Edwards Lifesciences during the third quarter worth $30,000. Prospera Private Wealth LLC bought a new stake in Edwards Lifesciences during the 3rd quarter worth approximately $32,000. Avior Wealth Management LLC raised its stake in shares of Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after purchasing an additional 308 shares during the last quarter. HHM Wealth Advisors LLC purchased a new position in shares of Edwards Lifesciences during the second quarter valued at approximately $55,000. Finally, Peoples Bank KS bought a new stake in shares of Edwards Lifesciences in the 3rd quarter worth $40,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Trading Up 0.7 %

NYSE EW opened at $74.16 on Thursday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The stock’s 50-day moving average is $71.38 and its 200-day moving average is $72.30. Edwards Lifesciences has a one year low of $58.93 and a one year high of $96.12. The firm has a market cap of $43.74 billion, a P/E ratio of 10.70, a P/E/G ratio of 3.61 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting analysts’ consensus estimates of $0.67. The business had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The firm’s quarterly revenue was up 8.9% on a year-over-year basis. During the same period last year, the business posted $0.59 earnings per share. Sell-side analysts anticipate that Edwards Lifesciences will post 2.56 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.